These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 33174299)

  • 1. Hydroxychloroquine use and COVID-19 concerns among alopecia patients: A cross-sectional survey study.
    Pathoulas JT; Flanagan KE; Walker CJ; Pupo Wiss IM; Hagigeorges D; Senna MM
    Dermatol Ther; 2020 Nov; 33(6):e14529. PubMed ID: 33174299
    [No Abstract]   [Full Text] [Related]  

  • 2. Shedding light on therapeutics in alopecia and their relevance to COVID-19.
    Fagan N; Meah N; York K; Bokhari L; Fletcher G; Chen G; Tobin DJ; Messenger A; Irvine AD; Sinclair R; Wall D
    Clin Dermatol; 2021; 39(1):76-83. PubMed ID: 33972056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in Individuals Treated With Long-Term Hydroxychloroquine: A Propensity Score-Matched Analysis of Cicatricial Alopecia Patients.
    Shaw KS; Yin L; Shah JK; Sally RA; Svigos KS; Adotama PU; Tuan HH; Shapiro J; Betensky RA; Lo Siccoa KI
    J Drugs Dermatol; 2021 Aug; 20(8):914-916. PubMed ID: 34397203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alopecia areata in a patient with SARS-Cov-2 infection.
    Sgubbi P; Savoia F; Calderoni O; Longo R; Stinchi C; Tabanelli M
    Dermatol Ther; 2020 Nov; 33(6):e14295. PubMed ID: 32909635
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) already treated with hydroxychloroquine (HCQ) compared with HCQ-naive patients with RA: a multicentre cross-sectional study.
    Khoubnasabjafari M; Jouyban A; Malek Mahdavi A; Namvar L; Esalatmanesh K; Hajialilo M; Dastgiri S; Soroush M; Safiri S; Khabbazi A
    Postgrad Med J; 2022 Mar; 98(e2):e92-e93. PubMed ID: 35232849
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.
    Diotallevi F; Campanati A; Radi G; Luchetti MM; Benfaremo D; Tagliati C; Simonetti O; Offidani A
    J Med Virol; 2021 Jan; 93(1):5-7. PubMed ID: 32691896
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics.
    Mendel A; Bernatsky S; Askanase A; Bae SC; Clarke AE; Costedoat-Chalumeau N; Gladman DD; Gordon C; Hanly J; Jacobsen S; Kalunian K; Mak A; Mosca M; Pons-Estel BA; Ruiz-Irastorza G; Urowitz M; Vinet É
    Ann Rheum Dis; 2021 Feb; 80(2):1-2. PubMed ID: 32586918
    [No Abstract]   [Full Text] [Related]  

  • 8. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.
    Mori N; Katayama M; Nukaga S
    J Microbiol Immunol Infect; 2021 Feb; 54(1):109-112. PubMed ID: 33054978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis.
    Tanni SE; Bacha HA; Naime A; Bernardo WM
    J Bras Pneumol; 2021; 47(5):e20210236. PubMed ID: 34669839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection.
    Yadav RM; Pate A; Shankarkumar A; Athalye S; Shinde S; Bargir UA; Pate M; Ganpule M; Pruthi M; Patil H; Madkaikar MR
    J Epidemiol Glob Health; 2021 Sep; 11(3):283-288. PubMed ID: 34514761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2.
    Ingraham NE; Boulware D; Sparks MA; Schacker T; Benson B; Sparks JA; Murray T; Connett J; Chipman JG; Charles A; Tignanelli CJ
    Crit Care; 2020 Apr; 24(1):182. PubMed ID: 32345336
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis.
    Rangel LK; Shah P; Lo Sicco K; Caplan AS; Femia A
    J Am Acad Dermatol; 2021 Jun; 84(6):1769-1772. PubMed ID: 33440213
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
    Barnabas RV; Brown ER; Bershteyn A; Stankiewicz Karita HC; Johnston C; Thorpe LE; Kottkamp A; Neuzil KM; Laufer MK; Deming M; Paasche-Orlow MK; Kissinger PJ; Luk A; Paolino K; Landovitz RJ; Hoffman R; Schaafsma TT; Krows ML; Thomas KK; Morrison S; Haugen HS; Kidoguchi L; Wener M; Greninger AL; Huang ML; Jerome KR; Wald A; Celum C; Chu HY; Baeten JM;
    Ann Intern Med; 2021 Mar; 174(3):344-352. PubMed ID: 33284679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.
    Mégarbane B
    Clin Toxicol (Phila); 2021 Jan; 59(1):70-71. PubMed ID: 32237918
    [No Abstract]   [Full Text] [Related]  

  • 15. Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous Thromboembolism.
    Perrella A; Orlando V; Trama U; Bernardi FF; Menditto E; Coscioni E
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection.
    Awad N; Schiller DS; Fulman M; Chak A
    Am J Health Syst Pharm; 2021 Mar; 78(8):689-696. PubMed ID: 33599721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summary for Patients: Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection.
    Ann Intern Med; 2021 Mar; 174(3):I16. PubMed ID: 33284685
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydroxychloroquine treatment for Alopecia Universalis: Report of six cases.
    Akdogan N; Ersoy-Evans S
    Australas J Dermatol; 2021 Feb; 62(1):e83-e85. PubMed ID: 32638352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study.
    Kamstrup P; Sivapalan P; Eklöf J; Hoyer N; Ulrik CS; Pedersen L; Lapperre TS; Harboe ZB; Bodtger U; Bojesen RD; Håkansson KEJ; Tidemandsen C; Armbruster K; Browatzki A; Meteran H; Meyer CN; Skaarup KG; Lassen MCH; Lundgren JD; Biering-Sørensen T; Jensen JU
    Int J Infect Dis; 2021 Jul; 108():370-376. PubMed ID: 34087484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.